secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0000950170-23-003930
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera reports Q4 2022 net loss $34.9M; cash $559.5M; Sanofi to start KT-474 Phase 2 in 2023
--------------------------------------------------------------------------------

- Net loss Q4 2022: $34.9M, full year $154.8M; cash and investments $559.5M as of Dec 31, 2022, runway into H2 2025.
- Collaboration revenue Q4 $16.1M, full year $46.8M; R&D expenses $43.1M Q4, $164.2M full year.
- Sanofi to initiate Phase 2 trial of KT-474 (IRAK4 degrader) in hidradenitis suppurativa and atopic dermatitis in 2023.
- Phase 1 trials for KT-333 (STAT3) and KT-413 (IRAKIMiD) ongoing; clinical activity data expected in 2023.
- KT-253 (MDM2) IND cleared; Phase 1 trial to start early 2023 in solid tumors and hematological malignancies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000095017023003930/0000950170-23-003930-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000095017023003930/kymr-20230223.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-003930

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer